Science Policy For All

Because science policy affects everyone.

Posts Tagged ‘funding

Science Policy Around the Web – June 7th, 2019

leave a comment »

By: Mary Weston, Ph.D.

Source: Pixabay

Pfizer had clues its blockbuster drug could prevent Alzheimer’s. Why didn’t it tell the world?

Last Tuesday, the Washington Post reported that the biopharmaceutical company Pfizer had hints that their rheumatoid arthritis drug Enbrel might reduce the risk of Alzheimer’s disease, but chose not to report these findings to the public.

In 2015, after analyzing hundreds of thousands of insurance claims, a team of Pfizer researchers observed that their anti-inflammatory drug Enbrel might also decrease the risk for Alzheimer’s by 64%. They recommended that the company conduct a costly clinical trial to prove the link but, after several years of internal debate, the company decided not to pursue the lead.  The question remains: why did Pfizer not release these findings to the scientific community?

Pfizer claims they did not pursue the research due to scientific considerations – they argue that since Enbrel cannot cross the blood-brain barrier and directly reach brain tissue, it is unlikely to prevent the debilitating neurodegenerative disease. Further, Pfizer claimed that they did not to report the research because the statistical findings did meet “rigorous scientific standards” and were concerned about misleading researchers down a false path. However, Pfizer is also losing its patent protection on Enbrel soon, meaning that generics will become available and the drug will be much less profitable, reducing any financial incentive for further research or clinical trials (likely to cost around $80 million).

Some in the scientific community are questioning Pfizer’s justification. Keenan Walker, an assistant professor of medicine at Johns Hopkins, argues that the scientific community benefits when the data is available, stating that ““[w]hether it was positive data or negative data, it gives us more information to make better informed decisions.’’

Several scientists argue that Pfizer’s results should be release because they could provide clues to combating the disease and slowing cognitive decline in its earliest stages. Specifically, recent research is hinting that inflammation may promote Alzheimer’s disease. Further, neurodegenerative research is notoriously challenging and there are no major drugs that treat Alzheimer’s. Even several recent phase 3 clinical trials have been halted because the drugs were not effective. Due to a lack of progress in the field, a couple large pharmaceutical companies, including Pfizer, have just closed their neurology-related research programs.

 (Christopher Rowland, Washington Post)

Trump administration halts fetal-tissue research by government scientists

The Trump administration has announced that government scientists will stop using human fetal tissue for research and is placing new limitations on researchers in academic settings who use federal funding from the NIH.

It is not entirely known how many research projects will be affected by the new regulations. Government scientists will be allowed to continue their current work, but are prohibited from acquiring new tissue samples. Current extramural research at universities and privately funded work can continue but any new grant proposals or renewals of existing projects must be approved by an ethics advisory board that will be formed.

In addition to halting government fetal tissue research, the administration has decided to cancel an ongoing HIV research contract with the University of California San Francisco, effectively ending a 30-year partnership. The project involves using fetal tissue to develop mouse models with human-like immune systems to develop new HIV therapies.

Use of fetal tissue is essential to for studying certain human biological processes, such as kidney development. Often biomedical research uses mice as substitutes of people, but in this case, murine kidney development is too different from their human counterparts to be of use. Some researchers fear that these new restrictions will set back certain research for years to come. Important areas of research that depend on using fetal tissue including HIV, neurodegeneration, human organ growth and regeneration, Zika (determining how/why the virus affects developing fetuses so severely), and certain types of vaccine development.

POLITICO reports that this decision was made after much debate between the White and the Department of Health and Human Services (HHS), which wanted a less restrictive policy. In a statement released Wednesday, HHS said that “promoting the dignity of human life from conception to natural death is one of the very top priorities of President Trump’s administration.” HHS is now reviewing whether sufficient alternatives to human fetal tissue exist and will be supporting the development and validation of these models. However, good alternatives for certain fetal tissue research are elusive and many scientists say that the tissue is essential for some fields.

 (Sara Reardon, Nature)

Have an interesting science policy link? Share it in the comments!

Advertisements

Written by sciencepolicyforall

June 7, 2019 at 6:11 pm

Science Policy Around the Web – May 10th, 2019

leave a comment »

By: Caroline Duncombe

Image by Steve Buissinne from Pixabay 

Drug prices will soon appear in many TV Ads

When watching an advertisement for a prescription drug on the television, a new addition will be added to that long list of side-effects: the product’s cost. On Wednesday, the health and human services secretary, Alex Azar, announced that the Trump administration will require pharmaceutical companies to state the priceof prescriptions in television advertisements in “legible” text, similar to the current standard of side effects. This policy will only apply to drugs whose whole-sale-price exceeds $35 per month.

            Such a change in policy has received substantial pushback from the drug industry. They claim that including the list price would confuse consumers who would potentially pay a different amount post-insurance (that is if you have insurance).  In addition, drug companies claim that such a requirement infringed on the companies’ First Amendment Rights. One of the driving forces behind the new policy change are the patient advocacy groups, who have pointed out that televised drug ads direct consumers to the higher priced medications.  The hope of such a policy is to potentially incentivize drug companies to lower their prices. Mr. Azar in a statement points out “If you’re ashamed of your drug prices, change your drug prices.” 

(Glenn Thrush and Katie Thomas, NYT)


Have an interesting science policy link? Share it in the comments!

Written by sciencepolicyforall

May 10, 2019 at 3:07 pm

Science Policy Around the Web – May 7th, 2019

leave a comment »

By: Allison Cross Ph.D.

Source: Flickr

Shake-up at NIH: Term limits for important positions would open new opportunities for women, minorities

Beginning next year, the NIH will be setting into motion a new policy implementing 12-year term limits for lab and branch chiefs in the NIH intramural program.  Currently, of the 272 chiefs overseeing the NIH intramural program, almost 20% of them have served in their position 20 or more years and, of those, over 5% have held their position for over 30 years.  

Individuals serving as lab and branch chiefs oversee administrative matters, mentoring, and recruitment for several labs or groups at NIH. With the current lack of turnover in chief positions, many feel it is hard to move up to a leadership position within NIH.  The new policy intends to change this, and to increase diversity among NIH leaders.  It is noted that women currently hold 26% of cheif positions, which is comparable to the percentage of women who hold tenured track positions at NIH.  

With implementation of the new policy, as many as half of the currently serving chiefs will be replaced in the next 5 years. The new policy indicates that the positions which become vacant will be filled through “open and transparent processes”.  To increase diversity of those holding these leadership positions, it will be important for NIH to have a diverse field of candidates capable of filling these positions. To help build the pool of candidates, the NIH is relying on the recently launched Distinguished Scholars Program, a program aimed at reducing the barriers to the recruitment and success of tenure-track female and minority faculty.

While some see the policy change as an opportunity to increase diversity in NIH leadership, others feel the change will have little impact, and still others question if leaders doing stellar jobs should really be replaced.  The current term limit policy change intended to take place next year will only affect the midlevel leadership positions, however, these changes may spread to higher level leadership positions in the future.   

(Jocelyn Kaiser, Science)


Senator’s queries prompt NIH and NSF to clarify how they monitor foreign research ties

There has been a recent increase in concern among members of Congress that foreign governments are taking advantage of open nature of the nation’s research enterprise. These concerns prompted senator Chuck Grassley (R–IA), chair of the Senate Committee on Finance, to send letters to the NIH, NSF, and DOD asking each agency to explain the practices they have in place to root out any illegal behavior.

These letters contain several questions for each agency to answer including 1) how the agency conducts background checks before awarding a researcher or institute a grant, 2) how much money is being spent “to identify and investigate potential violations of the rules concerning foreign affiliations and financial support for an investigator’s research, and 3) the number of institutions under investigation by the agencies “for employing individuals who failed to disclose contributions from foreign governments”.

Congress has received responses to these letters from NIH and NSF and is still waiting on a reply from DOD. Though both agencies that responded to the letter failed to answer all the questions from Senator Grassley, they used their responses to highlight changes being made to their grant application processes.  

In response to the question regarding background checks for grantees, both NIH and NSF explained that the agencies do no perform background checks.  In the NIH’s response to Senator Grassley, they explained that, in the last year, they reminded grantee institutions about their responsibility to notify NIH if a grantee is found guilty of scientific misconduct. Notably, the NIH currently requires that grantees disclose all “foreign components” of their research. The NSF used their response to explain the development of a web-based discloser form where researchers are to list “all sources current and pending support”. In a recent change by the NSF, they now also require all those applying for NSF grants to disclose if their proposal requests money for a foreign organization and, if so, to justify what the foreign collaborator offers that cannot be done at a US-based institution.   

With the responses from NIH and NSF leaving many of Senator Grassley’s questions unanswered, it is expected that further inquiries from Congress will continue.  

(Jeffrey Mervis, Science) 


Have an interesting science policy link? Share it in the comments!

Written by sciencepolicyforall

May 7, 2019 at 4:15 pm

Science Policy Around the Web – January 15, 2019

leave a comment »

By: Patrick Wright, Ph.D.

hierarchy-73338_640

Source: Pixabay

All Seven of the FDA’s Recent Commissioners Agree It Should be Independent—But Not on How to Accomplish It

From 2016 onward, former Food and Drug Administration (FDA) commissioners have called on Congress to make the FDA an independent agency that would no longer fall within the purview of the Department of Health and Human Services (HHS). The idea was initially proposed at the Aspen Ideas Festival in Colorado in 2016, which subsequently lead to the crafting of formal bipartisan white papers detailing the proposal to be used by current and upcoming administrations; these two companion white papers were recently released via the Aspen Institute and the January edition of Health Affairs.The co-authors of these white papers, seven former Commissioners of the FDA spanning 30 years of service, propose a new framework in which the FDA is reconfigured as an independent federal agency. The hope would be to make the FDA a cabinet-level agency (e.g. the Environmental Protection Agency) or an autonomous entity with powers similar to the Securities and Exchange Commission. These changes would help minimize the extent of bureaucracy (e.g. falling under HHS but funded as though it is part of the Department of Agriculture) and interference from other bodies. The FDA currently operates as one of eleven Operating Divisions under the HHS Secretary’s oversight, along with agencies such as the National Institutes of Health (NIH) and the Health Resources and Services Administration (HRSA).

The current structure allows other HHS agencies to have input on FDA policymaking, despite not necessarily having any familiarity with the innerworkings of FDA policy. David Kessler, the commissioner under George H.W. Bush and Bill Clinton, stated that there are “150 people in between the commissioner and the president, and they all think they’re your boss—that’s the problem”. A recent example of the results of external influence was in 2011 when the HHS Secretary at the time, Kathleen Sebelius, barred the decision by then-FDA Commissioner Dr. Margaret Hamburg to allow emergency contraception to be sold over the counter.

In the Aspen Institute white paper, the Commissioners state: “The goal of independence is to accommodate efficient, science-based decisionmaking by reengineering the processes through which FDA regulations and guidances flow from proposal to final form”. Many objectives that can be achieved with increased independence of the FDA as an entity are outlined in the paper, including the ability to enhance transparency of the Agency and thus sustain public confidence and to ensure predictable decisionmaking exclusively grounded in scientific evidence. Given the breadth of the FDA’s regulatory umbrella, newfound independence would have profound implications on the agency’s ability to address public health issues.

(Ike Swetlitz, StatNews)

Bipartisan Bill on Sexual Harassment Signals Strong Interest by Congress

A recently introduced bipartisan bill, the Combating Sexual Harassment in Science Act of 2019 (H.R. 36, 116thCongress), directs the National Science Foundation (NSF) to implement a number of strategies to combat sexual harassment in STEM academic and research settings. It was introduced by Eddie Bernice Johnson (D-TX) and Frank Lucas (R-OK), leading members from the House Committee on Science, Space, and Technology.

The bill allocates $17 million to the NSF Director to award grants to expand research efforts to “better understand the factors contributing to, and consequences of, sexual harassment affect individuals in the scientific, technical, engineering, and mathematics workforce, including students and trainees”; collect relevant national survey data on the issue; update the report on responsible conduct of research by the National Academies to include evidence-based practices for fostering a climate intolerant of sexual harassment; and work with the National Academies to assess the influence of sexual harassment in institutions of higher education on the career advancement of individuals within STEM. The NSF implemented a policy in 2018 that requires institutions receiving NSF funds to disclose whether they have put a funded investigator on administrative leave pending the conclusion of a harassment investigation or have found an investigator guilty of sexual harassment. Under this NSF policy, funds will be reallocated to another investigator at the institution; decisions to terminate a grant to an investigator found guilty of sexual harassment would depend on the capacity of the institution to continue the research without the original investigator.

However, H.R. 36 currently does not outline appropriate actions that federal agencies should take upon receipt of information from institutions of any harassment. To address this, Representative Jackie Speier (D-CA), aims to reintroduce a bill she wrote in 2016 that would require agencies to consider any finding of sexual harassment against a research when deciding to award funding. These collective efforts point to an increased drive by Congress to tangibly address this issuethat has been plaguing the scientific research spectrum.

(Jeffrey Mervis, Science)

 

 

 

Have an interesting science policy link? Share it in the comments!

Written by sciencepolicyforall

January 15, 2019 at 8:58 pm

Posted in Linkposts

Tagged with , , , ,

Science Policy Around the Web – January 4, 2019

leave a comment »

By: Saurav Seshadri, Ph.D.

united-states-2361405_1280

Source: Pixabay

U.S. shutdown begins: ‘It’s disheartening, … discouraging, … deflating’

As the third government shutdown of 2018 enters its third week, the extent of its impact on the scientific community is still unclear. The shutdown affects about a quarter of the federal government, including agencies such as the EPA, NIST, and NASA.  While some agencies, such as the NIH and CDC, have budgets approved through 2019 and can operate normally, many others have had to halt activities and place non-essential employees on leave without pay.  Such employees can’t even use their official email addresses until the government reopens. One of the hardest hit agencies is the National Science Foundation (NSF), whose current contingency plan only retains sixty out of about two thousand employees.  NSF has been forced to stop grant reviews and payments, and will have to reschedule many of its deadlines, which has real consequences for investigators – following a 16-day shutdown in 2013, NSF stated outright that because of the lapse in funding, ‘scientists experienced setbacks in furthering their research objectives’.  Other agencies are less affected; for example, drug reviews conducted by the FDA are largely funded by pharmaceutical companies and will continue without disruption.  However, the American Association for the Advancement of Science (AAAS) summarized many scientists’ concerns by stating that ‘any shutdown of the federal government can disrupt or delay research projects, lead to uncertainty over new research, and reduce researcher access to agency data and infrastructure’.

With their party’s majority in the House of Representatives made official on Thursday, Democrats immediately passed spending bills that would fund the government through early February.  However, these bills do not include $5.6 billion in funding for a border wall, and are therefore unlikely to end the shutdown: President Trump has insisted upon this figure, and Senate Republicans have indicated that they will not move forward any legislation that doesn’t meet Trump’s approval, despite previously supporting the same stopgap bill.  Post-holiday media coverage of struggling furloughed workersand lapsed public services has started to stoke public pressure, which will ultimately force an end to the shutdown.  But for now, both sides are more deeply entrenched in their positions than ever, and important science is falling by the wayside.

(Science News Staff, Science)

Brain circuits of compulsive drug addiction identified

Misuse of prescription opioid painkillers has reached epidemic proportions in America, and was declared a public health emergency by the Department of Health and Human Services in 2017.  According to recent estimates, there were 72,000 opioid overdose-related deaths that year, a 10% increase over the previous year.  The National Institute on Drug Abuse (NIDA) reports that about 20-30% of people prescribed opioids misuse them, and about 10% develop a disorder.  These statistics highlight the desperate need to understand the neurobiology of addiction, and specifically, how it can be reversed.  A recent study published in Nature makes significant progress in this direction.

The authors began by modeling a core feature of human addiction: compulsive behavior, or drug seeking in the face of negative consequences.  Mice were allowed to stimulate the release of dopamine (the neurotransmitter that signals ‘reward’ in response to drugs of abuse) by pressing a lever, which sent a laser pulse through an optical fiber to light-sensitized dopaminergic neurons in their brain.  Within a few days, mice were functionally addicted, and were self-stimulating up to 80 times per hour.  At this point, mice started to receive punishing electric foot shocks on every third stimulation.  This intervention caused the mice to split into two groups: those that stopped self-stimulating (40%, ‘renouncers’) and those that continued (60%, ‘perseverers’).

Having thus identified mice that showed characteristics of compulsive behavior, the authors turned their focus to the underlying circuitry.  They traced a neural pathway connecting the orbitofrontal cortex and the dorsal striatum, regions involved in decision making and action selection, which showed opposite patterns of activity in renouncers and perseverers.  Remarkably, reducing activity  in this pathway caused persevering mice to temporarily renounce stimulation, and weakening the connection itself extended this effect (up to about six days).

While the validity of comparing brain stimulation to drug abuse remains to be established, these results are still highly encouraging.  They provide a physical basis for aspects of addiction that are often poorly understood and harshly judged by society: why some addicts engage in seemingly irrational compulsive behaviors, and why individuals differ in their ability to break self-destructive cycles of addiction. Since several methods for modulating brain activity already exist, pinpointing exactly which circuits to target to combat addiction, as this study does, may be the key to recovery for many patients.

(Patricia Janak, Nature)

 

 

Have an interesting science policy link? Share it in the comments!

Written by sciencepolicyforall

January 4, 2019 at 10:01 am

Publications and Patents: Laying the foundation for future innovation and economic growth

leave a comment »

By: Xavier Bofill de Ros, Ph.D.

thought-2123970_1920.jpg

Source: Pixabay

 

Many hours on the laboratory bench made me wonder: What is the real impact of our science? How do the thousands of publications appearing in scientific magazines every month and the funds poured into research benefit our society? We all know history; Fleming’s research on mold resulted in the discovery of penicillin and saved millions of lives ever since, and GPS systems rely heavily on basic trigonometry. These examples embody the power of science as a driver of technological progress and motivates – public policies to support scientific research. For example, NIH receives $37 billion  annually to fund intramural and extramural biomedical research[1]. Some of this investment in research generates intellectual property, bringing back to the system private money derived from license agreements. For instance, the NIH Technology Transfer Office had an income of $138 million from royalties in 2015[2]. However, many critics are quick to point out that basic research rarely pays off in practical R&D.

To understand where we are we need to know where we are coming from. A big part of the current legislation that governs the intellectual property derived from publicly-funded research is inspired from the Patent and Trademark Law Amendments Act, also known as the Bayh–Dole Act passed in 1980. This act established that the ownership of inventions made with federally-funded research projects by universities, small business and non-profit institutions is entitled to them in preference to the government. Prior to that act, the government accumulated ownership to large numbers of patents derived from the $75 billion per year of funding dispersed through different agencies, however fewer than 5% of those patents were licensed[3]. In exchange for this new source of revenue, public money receiving institutions  are required to educate the research community about the patenting procedures and to protect the government’s interests on funded inventions among other requirements. Despite the criticisms for forcing consumers to “pay twice” for patented products, the economic impact of the Bayh-Dole Act has been important. Recent reports suggest that academic licenses to industry contributed between $148 to $591 billion per year to US gross domestic product (GDP)[4].

Besides economic performance, other approaches to assess the impact of scientific publications on intellectual property come from the bibliometric analysis of the prior art on issued patents. A recent study from Kellogg School of Management analyzed the content of 4.8 million patents and 32 million research articles to find out how research is connected to inventions[5]. By analyzing the prior art references of patents, and the references of these references, the authors revealed that 80% of research articles linked to a future patent. This connection is often indirect, since direct citations of research articles in patents only account for about 10%, but it quickly accumulates to 42% and 74% when second degree and third degree citations are included. This indicates that the vast majority of the publication corpus ends up in the pool of knowledge where inventions arise. The analysis of the distance between research articles and patents also revealed differences between fields of research. Areas such as “Computer science”, “Nanotechnology” and “Biochemistry and Molecular Biology” depict a more immediate impact on patents compared to others less easily applicable. The authors of the study also went on to address which institutions yield research articles with a more significant impact on patents. To this aim, they compared the publications from universities, government laboratories and publicly traded firms. Consistent with previous studies, firms’ scientific production is the most directly linked to patent production. However, universities and government publications follow at a very close distance, despite generally engaging with more long-term research goals.

Other less tangible contributions from academic research and industry take place through the open access of data, reagents or knowledge[6]. Examples of these are The Cancer Genome Atlas (TCGA) with genomic data from more than 11,000 patients, the Jackson Laboratory (JAX) collection and distribution of mouse strains of human diseases, or the Addgene repository, with a collection of more than 67.000 plasmids. Similarly, collaboration agreements like CRADAs (Cooperative Research and Development Agreements) allow industry to partner with academic labs[7]. Under such agreements, which can last years, researchers from academic labs and companies can engage with joint ventures by providing each other with resources, skills and funds. In these partnerships the ownership of any coming intellectual property is discussed upfront as well as first option rights for licensing. Such collaboration formulas have a positive impact on the market readiness of the technologies developed, when not directly shortening the pathway to market through the same industrial partner. Similarly, there’s also specific agreements allowing for to joint clinical trials, specifically for rare diseases, or to transfer research materials.

Overall, this illustrates that public investment can be used to generate innovation and economic growth through the right policy measures. Contrary to the belief that technological and scientific advances move independently, there’s a well-connected flow of ideas that permeate between patented inventions and scientific articles. There are already good incentives to the research communities to facilitate the collaboration between academia and industry. However, there’s still room for novel policies to further leverage what can be achieved through the public investment on research.

[1]https://www.nih.gov/about-nih/what-we-do/budget

[2]https://www.ott.nih.gov/sites/default/files/documents/pdfs/AR2016.pdf

[3]GAO/RCED-98-126 Transferring Federal Technology. Page 3.

[4]The Economic Contribution of  University/Nonprofit  Inventions in the United  States: 1996-2015. Biotechnology Innovation Organization and the Association of University Technology Managers

[5]Ahmadpoor M, Jones BF. “The dual frontier: Patented inventions and prior scientific advance”. Science. 2017 Aug 11;357(6351):583-587.

[6]Bubela T, FitzGerald GA, Gold ER. Recalibrating intellectual property rights to enhance translational research collaborations. Sci Transl Med. 2012 Feb 22;4(122).

[7]Ben-Menachem G, Ferguson SM, Balakrishnan K. Beyond Patents and Royalties: Perception and Reality of Doing Business with the NIH. J Biolaw Bus. 2006 Jan 1;24(1):17-20.

 

Have an interesting science policy link? Share it in the comments!

Written by sciencepolicyforall

November 28, 2018 at 10:41 am

Science Policy Around the Web – August 16, 2018

leave a comment »

By: Sarah Hawes, Ph.D.

20180816_Linkpost

source: pixabay

Scientific Discoveries

Ambitious ‘Human Cell Atlas’ Aims To Catalog Every Type Of Cell In The Body

You’ve no doubt heard of the Human Genome Project – a 15-year long endeavor to sequence the total human genome, fueled by 3 billion dollars and completed in 2003. But have you heard of the Human Cell Atlas Consortium? MIT biology professor and member of the Broad Institute Aviv Regev has led this collective of hundreds of international scientists since its foundation in 2016.

Just as the intent of the Human Genome Project was to sequence all our genetic material, the intent of the Consortium is to identify every single type of cell in the human body so that they can be investigated and understood independently, and in the complex context of cell-cell interactions, and their role in our physiology. This is a huge endeavor. We currently lack even a rough estimate of how many cell types exist. “People guess anything from the thousands to the tens of thousands. I’m not guessing,” Regev says. “I would rather actually get the measurements done and have a precise answer.”

And how does one delineate cell types in a meaningful way, to take these measurements? This is done by determining which genetic material a cell activates, i.e. which genes it mobilizes from quietly bundled DNA to RNA, and from there into a meaningful protein product to carry out the particular cellular functions defining a heart cell, or a lung cell, or a glial cell in the brain. The technology enabling description of a cells’ genetic character is called single-cell RNA sequencing.

In 2014, Aviv Regev, together with Steve McCarrol, and David Weitz at Harvard, improved on this process to substantially speed it up. “All of a sudden, we moved from something that was very laborious and we could do maybe a few dozen or a few hundred, to something where we could do many, many thousands in a 15- to 20-minute experiment,” Regev says. “We said, ‘That’s at the right scale that we could actually do the human body.’ And this is what they have set out to do.

Today, after just two years and 200 million in NIH funding, the Human Cell Atlas Consortium is beginning to bear fruit.

The first major Human Cell Atlas finding was published this month and simultaneously confirmed by a separate lab at Harvard Medical School. Both papers are published in the journal Nature, and report the definition of a new cell type in the windpipe which is responsible for creating a faulty protein linked to cystic fibrosis. Previously it was believed that the faulty protein originated in common cells lining the windpipe. Discovery of the new and rarer cells, dubbed ‘pulmonary ionocytes,’ will improve scientists’ ability to target faulty protein production by targeting the pulmonary ionocytes, thereby speeding up the development of treatments for cystic fibrosis.

A second consortium-related discovery appeared last week in the journal Science, in which British consortium members published the finding that childhood kidney cancer begins in a cell type which is distinct from the cells giving rise to kidney cancer in adults.

“We knew the lessons from the Human Genome Project were [that] rallying together the entire community would really let you get a full answer to a question. And that full answer will empower everyone to do better and faster and higher-resolution biology,” says Regev. Together, cataloguing all human cell types is predicted to take just another five to ten years. Discoveries building off this catalogue will dramatically enhance medical progress globally, and in perpetuity.

(Karen Weintraub, NPR)

Science and Innovation

It’s ‘Shark Tank’ For Global Health Inventions

A fascinating program to bolster innovation in global health, and particularly for impoverished mothers and children, is coming from a union between government agencies in the US, Norway, Korea, and the UK together with the Bill & Melinda Gates Foundation. This program, called Saving Lives At Birth: A Grand Challenge For Development, hosted a special conference in Washington, D.C. last week to empower global health inventors with the gift of pitch.

Nearly 500 applicants were winnowed down to ten participants, each of which presented global health innovations before a panel of judges rating them not on their science, but on their business plan – including target market, competition and revenue model.

Prior to presenting, each participant worked with consultants to enhance their slides and speeches. Rachele Haber-Thomson, one of the consultants, explained that many participants came from academia or non-profits. She said that while they knew how to write a grant, they needed help to capture the attention of investors looking for compact, business-savvy strategies.

Presentations were compact, seven-minute pitches on practical advances – describing a health problem, a solution, and convincing details on its implementation – all before taking questions from judges on feasibility, marketing, etc. The advances presented included an oxygen concentrator powered by running water, a medicine pouch to prevent transmission of HIV from mother to infant, a new subcutaneous contraceptive, and a system to generate disinfectant from salt and water. The winning pitch came from Gradian Health Systems, and was for a network of mobile medical training centers to enhance quality of care in areas with few physicians.

The prize for a winning pitch was not funding (though the audience included potential backers). Each participant had already been awarded $250,000 to $2 million from Saving Lives At Birth to develop their ideas prior to the conference. Instead of direct funding, the winner was given a choice between competing in a similar sales-pitch show-down in Berlin or else receiving free business-consulting.

As Sofia Stafford of USAID and Saving Lives At Birth puts it, “if these global health projects want to scale up, they need to know how to communicate their vision, grab investors’ interest and attract more funds.” Bearing this in mind, the July conference invokes the proverb “give a man a fish and he’ll eat for a day; teach a man to fish and he’ll eat for a lifetime.” Saving Lives At Birth does both.

(Vicky Hallett, NPR)

Have an interesting science policy link? Share it in the comments!

Written by sciencepolicyforall

August 16, 2018 at 4:31 pm